TY - JOUR
T1 - Anthropometrics and prognosis in diffuse large B-cell lymphoma
T2 - a multicentre study of 653 patients
AU - Bendtsen, Mette Dahl
AU - Munksgaard, Peter Svenssen
AU - Severinsen, Marianne Tang
AU - Bekric, Eric
AU - Brieghel, Christian
AU - Nielsen, Kristina Buchardi
AU - Brown, Peter de Nully
AU - Dybkær, Karen
AU - Johnsen, Hans Erik
AU - Bøgsted, Martin
AU - El-Galaly, Tarec Christoffer
PY - 2017
Y1 - 2017
N2 - Objective: The impact of body mass index (BMI) and body surface area (BSA) on survival in diffuse large B-cell lymphoma (DLBCL) is controversial. Recent studies show superior outcomes for overweight and obese patients. Patients and methods: A total of 653 R-CHOP(-like)-treated DLBCL patients were included in this retrospective cohort study. Patients, baseline clinicopathologic characteristics and treatment information were retrieved from the Danish Lymphoma Registry. Anthropometric measures were obtained from chemotherapy prescription charts. Results: Underweight (BMI <18.5 kg/m2) was associated with significantly worse progression-free survival (PFS) for male patients only in sex-stratified analyses (HR 3.92, 95% CI: 1.57–9.75, P = 0.003, for males; HR 1.65, 95% CI: 0.90–3.02, P = 0.107, for females). In multivariate analyses, underweight was associated with worse PFS for both sexes (HR 5.34, 95% CI: 2.07–13.79, P = 0.001, for males; HR 2.14, 95% CI: 1.12–4.08, P = 0.021, for females). Similar results were obtained in analyses of overall survival. In crude analyses, BSA <1.8 m2 was associated with worse PFS for men and women (HR 1.65, 95% CI: 1.03–2.65, P = 0.039, for men; HR 1.62, 95% CI: 1.03–2.56, P = 0.037, for women). In multivariate analyses, however, these associations diminished. Conclusions: Our study demonstrates that underweight DLBCL patients have worse outcomes following R-CHOP as compared to normal as well as overweight patients.
AB - Objective: The impact of body mass index (BMI) and body surface area (BSA) on survival in diffuse large B-cell lymphoma (DLBCL) is controversial. Recent studies show superior outcomes for overweight and obese patients. Patients and methods: A total of 653 R-CHOP(-like)-treated DLBCL patients were included in this retrospective cohort study. Patients, baseline clinicopathologic characteristics and treatment information were retrieved from the Danish Lymphoma Registry. Anthropometric measures were obtained from chemotherapy prescription charts. Results: Underweight (BMI <18.5 kg/m2) was associated with significantly worse progression-free survival (PFS) for male patients only in sex-stratified analyses (HR 3.92, 95% CI: 1.57–9.75, P = 0.003, for males; HR 1.65, 95% CI: 0.90–3.02, P = 0.107, for females). In multivariate analyses, underweight was associated with worse PFS for both sexes (HR 5.34, 95% CI: 2.07–13.79, P = 0.001, for males; HR 2.14, 95% CI: 1.12–4.08, P = 0.021, for females). Similar results were obtained in analyses of overall survival. In crude analyses, BSA <1.8 m2 was associated with worse PFS for men and women (HR 1.65, 95% CI: 1.03–2.65, P = 0.039, for men; HR 1.62, 95% CI: 1.03–2.56, P = 0.037, for women). In multivariate analyses, however, these associations diminished. Conclusions: Our study demonstrates that underweight DLBCL patients have worse outcomes following R-CHOP as compared to normal as well as overweight patients.
KW - body mass index
KW - body surface area
KW - diffuse large B-cell lymphoma
KW - prognosis
KW - survival
U2 - 10.1111/ejh.12835
DO - 10.1111/ejh.12835
M3 - Journal article
C2 - 27893172
AN - SCOPUS:85011416499
SN - 0902-4441
VL - 98
SP - 355
EP - 362
JO - European Journal of Haematology
JF - European Journal of Haematology
IS - 4
ER -